news
SARS antiviral nitric oxide could be used to treat SARS-CoV-2
The nitric oxide treatment used during the 2003 SARS epidemic could be used as an antiviral against SARS-CoV-2, researchers say.
List view / Grid view
Biopharmaceuticals
news
Antibodies from recovered COVID-19 patients inhibit SARS-CoV-2 infection in cells
Pre-clinical studies in cells and hamsters have shown that potent antibodies from COVID-19 patients can prevent infection from SARS-CoV-2.
webinar
Next generation strategies for cancer immunotherapy
24 September 2020 | By PerkinElmer
During this on-demand webinar, two leading researchers will discuss their innovative approaches to developing novel opportunities for immunotherapy treatments.
whitepaper
Webinar: Optimised workflow for rapid identification of neutralising antibodies against viral particles
Helping in the race to identify effective neutralising antibodies against the spike protein of SARS-CoV-2 virus as the COVID-19 global death rate continues to rise.
whitepaper
ebook: Get a front row view of your cells
Discover how you can simplify your workflow by combining microplate reading and imaging in a small footprint.
whitepaper
Webinar series: Considerations for successful CRISPR-based cell line engineering
Sign up for free weekly 5-10 min videos from Horizon’s expert cell line engineers to help you improve your CRISPR editing experiments.
video
On-demand webinar: Leveraging advances in predesigned synthetic sgRNA for highly functional and specific CRISPR-Cas9 gene knockout
This webinar explains how synthetic guide RNAs are stable, eliminate cloning and sequencing steps, and avoid innate immune responses and cytotoxicity.
article
Advancing cell therapies with engineered Tregs
Regulatory T cells (Tregs) play a key role in regulating our immune system and inflammatory processes. Sangamo Therapeutics is evaluating the potential of CAR-Tregs (Tregs genetically modified with a chimeric antigen receptor, or CAR) for the development of therapies for immunological diseases, such as Crohn’s disease and multiple sclerosis, as…
article
Antibody therapeutics for COVID-19
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…
whitepaper
Article: Tips for successful editing in T cells
Horizon article on the recipe for success for CRISPR editing in T cells.
whitepaper
Article: Common CRISPR pitfalls and how to avoid them
This article explains how to plan a gene-editing experiment. How to choose your biological system and what reagents to get for your experimental aim.
article
Antibodies In-Depth Focus 2020
Included in this in-depth focus are articles on antibody therapeutics to treat COVID-19, how AAV antibodies can be neutralised, the role of antibodies in cancer therapy and bispecific antibodies for immuno-oncology drugs.
whitepaper
Application note: Human iPS cells modified with Edit-R™ CRISPR-Cas9 reagents
Modify the genome and modulate expression of genes within human iPS cells with Dharmacon™ Edit-R CRISPR reagents.
webinar
Untangling gene expression complexity with pooled CRISPR screens coupled to single-cell transcriptome analysis
4 September 2020 | By Horizon Discovery
During this on-demand webinar we present data showing how Horizon’s CRISPRsc screening platform offers a streamlined approach to elucidating valuable and intriguing biological information that is critical to resolving complex biological questions.
news
Method to synthetically produce terpenes developed by researchers
Scientists have developed a synthetic biology process using enzymes to create three families of terpenes, potential starting points for new drugs.
